Amneal Pharmaceuticals (NASDAQ:AMRX) Releases Q1 2026 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) issued an update on its first quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.270-0.270 for the period, compared to the consensus estimate of 0.160. The company issued revenue guidance of $723.0 million-$723.0 million, compared to the consensus revenue estimate of $715.0 million. Amneal Pharmaceuticals also updated its FY 2026 guidance to 0.950-1.050 EPS.

Amneal Pharmaceuticals Trading Down 1.8%

AMRX stock opened at $13.02 on Wednesday. The firm has a 50 day moving average of $13.17 and a 200-day moving average of $12.53. Amneal Pharmaceuticals has a 12 month low of $7.02 and a 12 month high of $15.42. The firm has a market capitalization of $4.10 billion, a P/E ratio of 56.61 and a beta of 1.32.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.11. Amneal Pharmaceuticals had a net margin of 2.39% and a negative return on equity of 228.24%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.950-1.050 EPS and its Q1 2026 guidance at 0.270-0.270 EPS. Sell-side analysts predict that Amneal Pharmaceuticals will post 0.9 EPS for the current year.

Analysts Set New Price Targets

AMRX has been the subject of several research analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. UBS Group initiated coverage on shares of Amneal Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $19.00 target price for the company. Zacks Research lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Finally, Truist Financial lifted their target price on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Amneal Pharmaceuticals News Roundup

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q1 results and near-term guidance beat expectations: Amneal reported Q1 EPS of $0.26 vs. the $0.15 consensus and provided Q1 EPS guidance of $0.270 (above the $0.160 consensus) and revenue guidance of $723M vs. $715M consensus — evidence of stronger-than-expected core performance. AMRX Marketbeat earnings summary
• Positive Sentiment: Raised FY2026 outlook: Amneal set FY2026 EPS guidance of $0.95–1.05 (vs. $0.95 consensus) and revenue guidance of $3.1B–$3.2B, signaling management expects continued top-line growth for the year. GlobeNewswire release on acquisition and guidance
• Positive Sentiment: Acquisition to build biosimilars scale: Amneal agreed to acquire Kashiv BioSciences for up to $1.1B (cash + stock) to expand biologics development and manufacturing capabilities and target a large loss-of-exclusivity market — a strategic move to diversify into higher-margin complex therapies. The deal requires shareholder and regulatory approvals and is expected to close in H2 2026. Reuters: Amneal to buy Kashiv BioSciences
• Neutral Sentiment: Positive clinical news for Crexont supports product growth thesis: Interim Phase 4 ELEVATE?PD data show meaningful increases in “good on” time for Crexont in Parkinson’s patients, supporting commercial upside for key specialty products. Business Insider: Crexont Phase 4 results
• Negative Sentiment: Profitability and capital structure remain concerns: despite the beat, Amneal’s reported net margin is low (~2.4%) and return on equity is deeply negative (?228%), highlighting ongoing profitability and balance-sheet issues that could amplify market sensitivity to the Kashiv deal and any financing/dilution. AMRX Marketbeat financials

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds have recently bought and sold shares of AMRX. Westshore Wealth LLC bought a new stake in Amneal Pharmaceuticals during the third quarter valued at approximately $13,833,000. Morgan Stanley raised its stake in shares of Amneal Pharmaceuticals by 37.5% during the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after acquiring an additional 1,315,018 shares in the last quarter. Rubric Capital Management LP raised its stake in shares of Amneal Pharmaceuticals by 9.1% during the second quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company’s stock worth $94,737,000 after acquiring an additional 974,355 shares in the last quarter. Norges Bank purchased a new position in shares of Amneal Pharmaceuticals during the fourth quarter worth approximately $11,208,000. Finally, New York State Common Retirement Fund raised its stake in shares of Amneal Pharmaceuticals by 281.3% during the fourth quarter. New York State Common Retirement Fund now owns 841,193 shares of the company’s stock worth $10,599,000 after acquiring an additional 620,566 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.